Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders

Business Wire July 8, 2020

Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)

Business Wire July 4, 2020

New Findings on Gilead's Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults

Business Wire July 4, 2020

European Commission Grants Conditional Marketing Authorization for Gilead's Veklury® (remdesivir) for the Treatment of COVID-19

Business Wire July 3, 2020

Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual

Business Wire July 1, 2020

An Open Letter from Daniel O'Day, Chairman & CEO, Gilead Sciences

Business Wire June 29, 2020

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

Business Wire June 23, 2020

Javier Rodriguez Joins Gilead Sciences' Board of Directors

Business Wire June 16, 2020

Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe

Business Wire June 12, 2020

New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis

Business Wire June 5, 2020

Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis

Business Wire June 4, 2020

Mark Genovese Joins Gilead to Lead Clinical Development of Company's Inflammation Programs

Business Wire June 1, 2020

Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

Business Wire June 1, 2020

Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Business Wire May 29, 2020

Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia

Business Wire May 29, 2020

Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies

Business Wire May 27, 2020

Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis

Business Wire May 20, 2020

Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting

Business Wire May 13, 2020

Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19

Business Wire May 7, 2020

Gilead's Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19

Business Wire May 1, 2020